Answers are grounded in this paper and cite their sources.
Critical appraisal reveals potential overestimation of acitretin efficacy in mycosis fungoides, highlighting confounding from concurrent therapies and historical controls.
This correspondence highlights important methodological limitations in a recently published retrospective cohort evaluating acitretin in mycosis fungoides. Inclusion of stage IA patients, extensive use of concurrent skin directed therapies, and comparison with historical bexarotene trial data complicate attribution of clinical outcomes to acitretin alone. These factors may lead to overestimation of efficacy and underscore the need for cautious interpretation of retrospective analyses in cutaneous T cell lymphoma.
No takes yet. Share an insight, caveat, or question.
Oleg E. Akilov (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: